156 related articles for article (PubMed ID: 26943987)
1. A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
Roviello G; Milani M; Gobbi A; Cappelletti MR; Zanotti L; Senti C; Bottini A; Strina C; Sigala S; Generali D
Clin Breast Cancer; 2016 Jun; 16(3):e57-9. PubMed ID: 26943987
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
Lee JS; Yost SE; Blanchard S; Schmolze D; Yin HH; Pillai R; Robinson K; Tang A; Martinez N; Portnow J; Wen W; Yim JH; Brauer HA; Ren Y; Luu T; Mortimer J; Yuan Y
Breast Cancer Res; 2019 Nov; 21(1):119. PubMed ID: 31703728
[TBL] [Abstract][Full Text] [Related]
3. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
4. A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
Sakiyama T; Tsurutani J; Iwasa T; Kawakami H; Nonagase Y; Yoshida T; Tanaka K; Fujisaka Y; Kurata T; Komoike Y; Nishio K; Nakagawa K
Br J Cancer; 2015 Mar; 112(5):819-24. PubMed ID: 25654665
[TBL] [Abstract][Full Text] [Related]
5. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
Twelves C; Anthoney A; Savulsky CI; Guo M; Reyderman L; Cresti N; Semiglazov V; Timcheva C; Zubairi I; Morrison R; Plummer R; Evans TRJ
Br J Cancer; 2019 Mar; 120(6):579-586. PubMed ID: 30783204
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
Yonemori K; Shimomura A; Yasojima H; Masuda N; Aogi K; Takahashi M; Naito Y; Shimizu S; Nakamura R; Hashimoto J; Yamamoto H; Hirakawa A; Michimae H; Hamada A; Yoshida T; Sukigara T; Tamura K; Fujiwara Y
Eur J Cancer; 2019 Mar; 109():84-91. PubMed ID: 30703739
[TBL] [Abstract][Full Text] [Related]
7. Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study.
Tolaney SM; Kalinsky K; Kaklamani VG; D'Adamo DR; Aktan G; Tsai ML; O'Regan RM; Kaufman PA; Wilks ST; Andreopoulou E; Patt DA; Yuan Y; Wang G; Savulsky C; Xing D; Kleynerman E; Karantza V; Diab S
Clin Cancer Res; 2021 Jun; 27(11):3061-3068. PubMed ID: 33727258
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
9. A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.
Goel S; Swami U; Kumar K; Dittrich C; Reyderman L; Jain M; Aisner J; Song J; Petrylak DP
Cancer Chemother Pharmacol; 2019 Sep; 84(3):567-578. PubMed ID: 31190276
[TBL] [Abstract][Full Text] [Related]
10. An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.
Waller CF; Vynnychenko I; Bondarenko I; Shparyk Y; Hodge JP; Freeman A; Huber B; Lieberman R; Shelton MJ; Dave H
Clin Lung Cancer; 2015 Mar; 16(2):92-9. PubMed ID: 25458558
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
Hattori M; Ishiguro H; Masuda N; Yoshimura A; Ohtani S; Yasojima H; Morita S; Ohno S; Iwata H
Breast Cancer; 2018 Jan; 25(1):108-117. PubMed ID: 28861862
[TBL] [Abstract][Full Text] [Related]
12. Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
Marmé F; Gomez-Roca C; Graudenz K; Huang F; Lettieri J; Peña C; Trnkova ZJ; Eucker J
Cancer Chemother Pharmacol; 2018 Apr; 81(4):727-737. PubMed ID: 29468456
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
Evans TRJ; Dean E; Molife LR; Lopez J; Ranson M; El-Khouly F; Zubairi I; Savulsky C; Reyderman L; Jia Y; Sweeting L; Greystoke A; Barriuso J; Kristeleit R
Br J Cancer; 2019 Feb; 120(4):379-386. PubMed ID: 30679780
[TBL] [Abstract][Full Text] [Related]
14. Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
Smith JW; Vukelja S; Hoffman AD; Jones VE; McIntyre K; Berrak E; Song JX; O'Shaughnessy J
Clin Breast Cancer; 2016 Feb; 16(1):31-7. PubMed ID: 26433876
[TBL] [Abstract][Full Text] [Related]
15. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
[TBL] [Abstract][Full Text] [Related]
16. Eribulin mesylate in patients with refractory cancers: a Phase I study.
Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
Mukai H; Saeki T; Shimada K; Naito Y; Matsubara N; Nakanishi T; Obaishi H; Namiki M; Sasaki Y
Invest New Drugs; 2015 Feb; 33(1):119-27. PubMed ID: 25242374
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
[TBL] [Abstract][Full Text] [Related]
19. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Curigliano G; Martin M; Jhaveri K; Beck JT; Tortora G; Fazio N; Maur M; Hubner RA; Lahner H; Donnet V; Ajipa O; Li Z; Blumenstein L; Andre F
Eur J Cancer; 2021 Jul; 151():49-62. PubMed ID: 33964572
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
